dantrolene has been researched along with Tachycardia, Ventricular in 11 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this trial will clarify the efficacy and safety of dantrolene for ventricular arrhythmia, as well as mortality and morbidity in patients with chronic heart failure and reduced ejection fraction during guideline-directed medical treatment." | 9.34 | A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. ( Akashi, S; Furutani, Y; Harada, M; Hiromoto, M; Hisamatsu, Y; Ikeda, Y; Kawamura, S; Kobayashi, S; Kohno, M; Michishige, H; Nakamura, Y; Obayashi, M; Oda, T; Omura, M; Ono, S; Satoh, A; Seki, K; Uchida, K; Wakeyama, T; Yano, M, 2020) |
| "The results of this trial will clarify the efficacy and safety of dantrolene for ventricular arrhythmia, as well as mortality and morbidity in patients with chronic heart failure and reduced ejection fraction during guideline-directed medical treatment." | 5.34 | A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design. ( Akashi, S; Furutani, Y; Harada, M; Hiromoto, M; Hisamatsu, Y; Ikeda, Y; Kawamura, S; Kobayashi, S; Kohno, M; Michishige, H; Nakamura, Y; Obayashi, M; Oda, T; Omura, M; Ono, S; Satoh, A; Seki, K; Uchida, K; Wakeyama, T; Yano, M, 2020) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inherited arrhythmogenic disorder." | 2.80 | Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models. ( Aalto-Setälä, K; Kontula, K; Lahtinen, AM; Paavola, J; Penttinen, K; Swan, H; Vanninen, S, 2015) |
| "In catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited disease characterized by stress-induced ventricular arrhythmias in young patients with structurally normal hearts, autosomal dominant mutations in RYR2 or recessive mutations in calsequestrin lead to aberrant diastolic Ca(2+) release from the SR causing arrhythmogenic delayed after depolarizations (DADs)." | 1.38 | Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. ( Bellin, M; Dirschinger, RJ; Dorn, T; Goedel, A; Gudermann, T; Iop, L; Jung, CB; Lam, JT; Laugwitz, KL; Lipp, P; Mederos y Schnitzler, M; Moretti, A; Pfeiffer, S; Ruppenthal, S; Seyfarth, M; Sinnecker, D; Storch, U, 2012) |
| "All knockin mice we examined produced ventricular tachycardia after exercise on a treadmill." | 1.37 | Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia. ( Doi, M; Fukuda, M; Hino, A; Ikeda, Y; Ikemoto, N; Kobayashi, S; Matsuzaki, M; Okuda, S; Ono, M; Suetomi, T; Tateishi, H; Uchinoumi, H; Xu, X; Yamamoto, T; Yano, M, 2011) |
| "Pre-treatment with dantrolene (for 7-10 days) significantly inhibited the inducible VT (P<0." | 1.36 | Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. ( Doi, M; Kobayashi, S; Matsuzaki, M; Oda, T; Okuda, S; Ono, M; Suetomi, T; Susa, T; Tateishi, H; Uchinoumi, H; Xu, X; Yamamoto, T; Yano, M, 2010) |
| "Rhabdomyolysis was suspected." | 1.35 | Rhabdomyolysis after liver transplantation: a case report. ( Chen, CL; Chen, KH; Cheng, KW; Cheng, YF; Chiu, KW; Concejero, AM; Huang, CJ; Huang, TL; Jawan, B; Lin, CC; Liu, YW; Wang, CC; Wang, CS; Wang, SH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, S | 2 |
| Kobayashi, S | 5 |
| Chang, Y | 1 |
| Nawata, J | 1 |
| Yoshitomi, R | 1 |
| Tanaka, S | 1 |
| Kohno, M | 3 |
| Nakamura, Y | 3 |
| Ishiguchi, H | 1 |
| Suetomi, T | 3 |
| Uchinoumi, H | 5 |
| Oda, T | 5 |
| Okuda, S | 4 |
| Okamura, T | 1 |
| Yamamoto, T | 4 |
| Yano, M | 5 |
| Kajii, T | 1 |
| Shiba, S | 1 |
| Tamitani, M | 1 |
| Nanno, T | 1 |
| Kato, T | 1 |
| Wakeyama, T | 1 |
| Ono, S | 1 |
| Ikeda, Y | 2 |
| Omura, M | 1 |
| Hisamatsu, Y | 1 |
| Seki, K | 1 |
| Satoh, A | 1 |
| Hiromoto, M | 1 |
| Akashi, S | 1 |
| Uchida, K | 1 |
| Harada, M | 1 |
| Furutani, Y | 1 |
| Kawamura, S | 1 |
| Obayashi, M | 1 |
| Michishige, H | 1 |
| Juhola, M | 1 |
| Penttinen, K | 2 |
| Joutsijoki, H | 1 |
| Aalto-Setälä, K | 2 |
| Seidel, M | 1 |
| Thomas, NL | 1 |
| Williams, AJ | 1 |
| Lai, FA | 1 |
| Zissimopoulos, S | 1 |
| Swan, H | 1 |
| Vanninen, S | 1 |
| Paavola, J | 1 |
| Lahtinen, AM | 1 |
| Kontula, K | 1 |
| Yang, Y | 1 |
| Li, N | 1 |
| Alsina, KM | 1 |
| Puglisi, JL | 1 |
| Chen-Izu, Y | 1 |
| Cornea, RL | 1 |
| Wehrens, XHT | 1 |
| Bers, DM | 1 |
| Huang, CJ | 1 |
| Chen, CL | 1 |
| Wang, CS | 1 |
| Cheng, KW | 1 |
| Chen, KH | 1 |
| Wang, CC | 1 |
| Concejero, AM | 1 |
| Cheng, YF | 1 |
| Huang, TL | 1 |
| Chiu, KW | 1 |
| Wang, SH | 1 |
| Lin, CC | 1 |
| Liu, YW | 1 |
| Jawan, B | 1 |
| Susa, T | 1 |
| Ono, M | 2 |
| Xu, X | 2 |
| Tateishi, H | 2 |
| Doi, M | 2 |
| Matsuzaki, M | 2 |
| Fukuda, M | 1 |
| Hino, A | 1 |
| Ikemoto, N | 1 |
| Jung, CB | 1 |
| Moretti, A | 1 |
| Mederos y Schnitzler, M | 1 |
| Iop, L | 1 |
| Storch, U | 1 |
| Bellin, M | 1 |
| Dorn, T | 1 |
| Ruppenthal, S | 1 |
| Pfeiffer, S | 1 |
| Goedel, A | 1 |
| Dirschinger, RJ | 1 |
| Seyfarth, M | 1 |
| Lam, JT | 1 |
| Sinnecker, D | 1 |
| Gudermann, T | 1 |
| Lipp, P | 1 |
| Laugwitz, KL | 1 |
2 trials available for dantrolene and Tachycardia, Ventricular
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design.
Topics: Chronic Disease; Dantrolene; Double-Blind Method; Female; Heart Failure; Humans; Male; Morbidity; Re | 2020 |
Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC Models.
Topics: Adult; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cell Differentiation; Dantrol | 2015 |
9 other studies available for dantrolene and Tachycardia, Ventricular
| Article | Year |
|---|---|
RyR2-targeting therapy prevents left ventricular remodeling and ventricular tachycardia in post-infarction heart failure.
Topics: Animals; Arrhythmias, Cardiac; Calmodulin; Dantrolene; Heart Failure; Mice; Myocardial Infarction; M | 2023 |
Dantrolene prevents ventricular tachycardia by stabilizing the ryanodine receptor in pressure- overload induced failing hearts.
Topics: Animals; Dantrolene; Heart Failure; Mice; Muscle Relaxants, Central; Pressure; Protective Agents; Ry | 2020 |
Analysis of Drug Effects on iPSC Cardiomyocytes with Machine Learning.
Topics: Adrenergic Agonists; Calcium Signaling; Cell Line; Dantrolene; Epinephrine; Humans; Induced Pluripot | 2021 |
Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors.
Topics: Amino Acid Substitution; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricu | 2015 |
CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift.
Topics: Animals; Calcium; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calmodulin; | 2016 |
Rhabdomyolysis after liver transplantation: a case report.
Topics: Arrhythmias, Cardiac; Biliary Atresia; Child, Preschool; Dantrolene; Female; Humans; Liver Transplan | 2008 |
Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model.
Topics: Adrenergic alpha-Agonists; Animals; Anti-Arrhythmia Agents; Calcium; Dantrolene; Disease Models, Ani | 2010 |
Mutation-linked defective interdomain interactions within ryanodine receptor cause aberrant Ca²⁺release leading to catecholaminergic polymorphic ventricular tachycardia.
Topics: Allosteric Site; Amino Acid Sequence; Amino Acid Substitution; Animals; Calcium; Dantrolene; Diastol | 2011 |
Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.
Topics: Adult; Calcium; Cells, Cultured; Dantrolene; Female; Humans; Induced Pluripotent Stem Cells; Ion Tra | 2012 |